News Innovative PNH Drug Licancopan Approved in China: Oral CFB Inhibitor for Dual Hemolysis Control DengYueMed, DengYue 22/08/2026
News Anflekitug Approved in China: A New IL-1β Targeted Treatment Option for Acute Gouty Arthritis DengYueMed, DengYue 21/08/2026
News Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market DengYueMed, DengYue 14/08/2026
News Tinengotinib Approved for Cholangiocarcinoma in China, Addressing FGFR Inhibitor Resistance DengYueMed, DengYue 13/08/2026
News Recibokibart Approved for GPP: China-Developed IL-36R Antibody Brings a New Treatment Option for Generalized Pustular Psoriasis DengYueMed, DengYue 04/08/2026
News Insulin Sudelidec Approved for Type 2 Diabetes in China: A New Chinese Innovation in the Long-Acting Basal Insulin Market DengYueMed, DengYue 30/07/2026
News Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS) DengYueMed, DengYue 28/07/2026
News Ciprocopan Approved in China as the World’s First Once-Daily Oral CFB Inhibitor for PNH DengYueMed, DengYue 23/07/2026
News Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy DengYueMed, DengYue 22/07/2026
News The First Approved ADC for Esophageal Squamous Cell Carcinoma (ESCC): How Izalontamab Brengitecan Is Transforming Treatment DengYueMed, DengYue 21/07/2026
News Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent DengYueMed, DengYue 17/07/2026
News Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development DengYueMed, DengYue 16/07/2026